ArticleMolecular genetics & genomic medicine2021
LncRNA-H19 gene plays a significant role in regulating glioma cell function.
Article in Molecular genetics & genomic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- TMEM161B-AS1: a pivotal long non-coding RNA in the pathogenesis of glioblastoma revealed by Mendelian randomization analysis.International journal of clinical and experimental pathology · 2026Article
- Combined Effect of Conventional Chemotherapy with Epigenetic Modulators on Glioblastoma.Genes · 2025Article
- The relationship between long noncoding RNAInternational journal of medical sciences · 2025Article
- A prominent role of LncRNA H19 in H. pylori CagA induced DNA damage response and cell malignancy.Scientific reports · 2024Article
- 5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioma is an aggressive adult primary cancer, and is characterized by low cure rate, poor prognosis, and high recurrence. The present study aimed to investigate the effect of lncRNA-H19 gene silencing on glioma cell function.
methodslncRNA-H19 interference vector (LV3-si-H19) and negative control vector (LV3-NC) were stably transfected into U251 and U87-MG cells, respectively. Quantitative real-time PCR (qRT-PCR) was performed to investigate the expression of lncRNA-H19. Cell proliferation capacity was tested by adopting cell counting kit (CCK8), and propidium iodide (PI) was used for cell cycle analysis. Meanwhile, flow cytometry (FCM) method was used to investigate cell apoptosis, cell migration capacity was detected via wound healing and transwell experiments, and sphere-forming ability was examined in serum-free suspension culture. Additionally, glioma animal models were conducted through injecting U251 cells to estimate the effects of lncRNA-H19 on glioma growth in vivo.
resultsKnocking down lncRNA-H19 gene could effectively suppress the proliferation of U251 and U87-MG cells. The knockdown of lncRNA-H19 remarkably inhibited the migration and blocked cycle progressions of U251 and U87-MG cells, yet, no obvious changes were observed in cell apoptosis. Besides, inhibiting lncRNA-H19 expression could attenuate sphere-forming function of U251 and U87-MG cells. Additionally, tumor volume and weight were significantly reduced in rats injected with U251 LV-si-H19 cell line compared to untransfected and negative controls, when survival time was obviously prolonged in U251 LV-si-H19 injection groups.
conclusionLncRNA-H19 gene plays a carcinogenic role in glioma progression via enhancing aggressive behavior of glioma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.